Results 21 to 30 of about 539,046 (150)

Structures of native SV2A reveal the binding mode for tetanus neurotoxin and anti-epileptic racetams

Nature Communications
The synaptic vesicle glycoprotein 2A (SV2A) is a synaptic vesicle (SV) resident with homology to the major facilitator superfamily (MFS) and essential in vertebrate neurotransmission.
Stephan Schenck, Toon Laeremans, Jan Steyaert, Janine D. Brunner   +3 more
doaj   +2 more sources

Comparative neuroprotective and cognitive effects of human umbilical cord mesenchymal stem cells, secretome, and exosomes in a rat model of pilocarpine-induced epilepsy [PDF]

Veterinary World
Background and Aim: Epilepsy is a chronic neurological disorder characterized by recurrent seizures, neuronal degeneration, and cognitive impairment. Current antiepileptic therapies mainly control seizures and do not effectively prevent epileptogenesis ...
Sri Hastuti, Indra Bactiar, Yetty Ramli, Imran Imran, Rinaldi Idroes   +4 more
doaj   +2 more sources

Synthesis and in vivo evaluation of [¹⁸F]UCB-J for PET imaging of synaptic vesicle glycoprotein 2A (SV2A). [PDF]

Eur J Nucl Med Mol Imaging, 2019
Synaptic abnormalities have been implicated in a variety of neuropsychiatric disorders, including epilepsy, Alzheimer's disease, and schizophrenia. Hence, PET imaging of the synaptic vesicle glycoprotein 2A (SV2A) may be a valuable in vivo biomarker for neurologic and psychiatric diseases. We previously developed [11C]UCB-J, a PET radiotracer with high
Li S, Cai Z, Zhang W, Holden D, Lin SF, Finnema SJ, Shirali A, Ropchan J, Carre S, Mercier J, Carson RE, Nabulsi N, Huang Y.   +12 more
europepmc   +4 more sources

Improved synthesis of SV2A targeting radiotracer [11C]UCB-J

EJNMMI Radiopharmacy and Chemistry, 2019
Introduction [11C]UCB-J is a tracer developed for PET (positron emission tomography) that has high affinity towards synaptic vesicle glycoprotein 2A (SV2A), a protein believed to participate in the regulation of neurotransmitter release in neurons and ...
Johanna Rokka, Eva Schlein, Jonas Eriksson   +2 more
doaj   +2 more sources

Integration of postmortem amygdala expression profiling, GWAS, and functional cell culture assays: neuroticism-associated synaptic vesicle glycoprotein 2A (SV2A) gene is regulated by miR-133a and miR-218. [PDF]

Transl Psychiatry, 2020
AbstractRecent genome-wide studies have begun to identify gene variants, expression profiles, and regulators associated with neuroticism, anxiety disorders, and depression. We conducted a set of experimental cell culture studies of gene regulation by micro RNAs (miRNAs), based on genome-wide transcriptome, proteome, and miRNA expression data from ...
Jurkiewicz M, Moser D, Koller A, Yu L, Chen EI, Bennett DA, Canli T.   +6 more
europepmc   +4 more sources

Positron Emission Computed Tomography Imaging of Synaptic Vesicle Glycoprotein 2A in Alzheimer’s Disease

Frontiers in Aging Neuroscience, 2021
Alzheimer’s disease (AD) is the most common neurodegenerative disorder seen in age-dependent dementia. There is currently no effective treatment for AD, which may be attributed in part to lack of a clear underlying mechanism.
Yanyan Kong, Shibo Zhang, Lin Huang, Chencheng Zhang, Fang Xie, Zhengwei Zhang, Qi Huang, Donglang Jiang, Junpeng Li, Weiyan Zhou, Tao Hua, Bomin Sun, Jiao Wang, Yihui Guan   +13 more
doaj   +1 more source

Identification of pre-synaptic density networks using [11C]UCB-J PET imaging and ICA in mice

NeuroImage, 2022
Background: Synaptic vesicle glycoprotein 2A (SV2A) is a vesicle glycoprotein involved in neurotransmitter release. SV2A is located on the pre-synaptic terminals of neurons and visualized using the radioligand [11C]UCB-J and positron emission tomography (
Jordy Akkermans, Franziska Zajicek, Alan Miranda, Mohit H. Adhikari, Daniele Bertoglio   +4 more
doaj   +1 more source

PET Imaging of Synaptic Density: Challenges and Opportunities of Synaptic Vesicle Glycoprotein 2A PET in Small Animal Imaging

Frontiers in Neuroscience, 2022
The development of novel PET imaging agents for synaptic vesicle glycoprotein 2A (SV2A) allowed for the in vivo detection of synaptic density changes, which are correlated with the progression and severity of a variety of neuropsychiatric diseases. While
Takuya Toyonaga, Arman Fesharaki-Zadeh, Arman Fesharaki-Zadeh, Stephen M. Strittmatter, Stephen M. Strittmatter, Richard E. Carson, Zhengxin Cai   +6 more
doaj   +1 more source

Connectivity Mapping Using a Novel sv2a Loss-of-Function Zebrafish Epilepsy Model as a Powerful Strategy for Anti-epileptic Drug Discovery

Frontiers in Molecular Neuroscience, 2022
Synaptic vesicle glycoprotein 2A (SV2A) regulates action potential-dependent neurotransmitter release and is commonly known as the primary binding site of an approved anti-epileptic drug, levetiracetam.
Yifan Zhang, Lise Heylen, Michèle Partoens, James D. Mills, James D. Mills, James D. Mills, Rafal M. Kaminski, Rafal M. Kaminski, Patrice Godard, Michel Gillard, Peter A. M. de Witte, Aleksandra Siekierska   +11 more
doaj   +1 more source

Exploring Synaptic Vesicle Glycoprotein 2A (SV2A) Alterations in Alzheimer's Disease Using Targeted Mass Spectrometry [PDF]

Alzheimers Dement
Abstract Background SV2A levels are decreased in Alzheimer's disease (AD) brains, as revealed by Positron Emission Tomography (PET). Whether this decrease is due to synapse loss or SV2A protein loss remains unclear, hindering treatment development and interpretation of SV2A PET as a biomarker ...
Zetterberg H.
europepmc   +2 more sources